Evidence map›Paper›PMID 15655564›Full record

Trial reportMolecular psychiatry2005

Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response.

C Maddock, S Landau, K Barry, P Maulayah, M Hotopf, A J Cleare, S Norris, C M Pariante

Abstract readClinical TrialLetter
PubMed Publisher
In one paragraph

Trial report in Molecular psychiatry, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Glucocorticoids, cytokines and brain abnormalities in depression.Progress in neuro-psychopharmacology & biological psychiatry · 2011
    Review
  14. Article
  15. IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2011
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

C Maddock
S Landau
K Barry
P Maulayah
M Hotopf
A J Cleare
S Norris
C M Pariante

Funding

Medical Research Council G108/603
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAntiviral AgentsAnxietyDepressionDrug CarriersDrug Therapy, CombinationFatigueFemaleHepatitis C, ChronicHumansInterferon-alphaInterferon alpha-2MaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsAntiviral AgentsDrug CarriersInterferon-alphaInterferon alpha-2peginterferon alfa-2bPolyethylene GlycolsRecombinant ProteinsRibavirin

Identifiers

PMID15655564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.